2019
Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled 96-Week Data from Three Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT)
Blauvelt A, Strober B, Langley R, Kavanagh S, Arendt C, Boehnlein M, Lebwohl M, Reich K. Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled 96-Week Data from Three Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT). SKIN The Journal Of Cutaneous Medicine 2019, 3: s39. DOI: 10.25251/skin.3.supp.39.Peer-Reviewed Original Research
2018
Safety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks' Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies
Blauvelt A, Strober B, Langley R, Burge D, Pisenti L, Yassine M, Kavanagh S, Arendt C, Rolleri R, Reich K. Safety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks' Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies. SKIN The Journal Of Cutaneous Medicine 2018, 2: s16. DOI: 10.25251/skin.2.supp.16.Peer-Reviewed Original Research
2014
Tumor necrosis factor inhibitors in psoriasis: an update.
Kerdel F, Strober B. Tumor necrosis factor inhibitors in psoriasis: an update. Seminars In Cutaneous Medicine And Surgery 2014, 33: s31-6. PMID: 24979543, DOI: 10.12788/j.sder.0066.Peer-Reviewed Original ResearchConceptsTumor necrosis factorTNF inhibitorsNecrosis factor inhibitorsTreatment of psoriasisCertolizumab pegolPlaque psoriasisPsoriatic arthritisFactor inhibitorsClinical trialsNecrosis factorPsoriasisRecent evidenceInhibitorsEfficacyGolimumabInfliximabPegolAdalimumabEtanerceptArthritisImmunogenicity
2010
Disseminated superficial porokeratosis.
Brauer J, Mandal R, Walters R, Solomon G, Kundu R, Strober B. Disseminated superficial porokeratosis. Dermatology Online Journal 2010, 16: 20. PMID: 21163171, DOI: 10.5070/d395d16725.Peer-Reviewed Original ResearchConceptsPsoriatic arthritisSuperficial porokeratosisDiagnosis of porokeratosisOne-week historySetting of immunosuppressionDisseminated superficial porokeratosisCertolizumab pegolPruritic lesionsBiopsy specimenPorokeratosisArthritisDiagnosisPink spotsPegolImmunosuppressionPsoriasisMethotrexateTherapyLesionsExtremitiesWeeksWomen